» Articles » PMID: 36697158

Cause-Specific Mortality in Patients With Advanced Chronic Kidney Disease in the ISCHEMIA-CKD Trial

Abstract

Background: In ISCHEMIA-CKD, 777 patients with advanced chronic kidney disease and chronic coronary disease had similar all-cause mortality with either an initial invasive or conservative strategy (27.2% vs 27.8%, respectively).

Objectives: This prespecified secondary analysis from ISCHEMIA-CKD (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease) was conducted to determine whether an initial invasive strategy compared with a conservative strategy decreased the incidence of cardiovascular (CV) vs non-CV causes of death.

Methods: Three-year cumulative incidences were calculated for the adjudicated cause of death. Overall and cause-specific death by treatment strategy were analyzed using Cox models adjusted for baseline covariates. The association between cause of death, risk factors, and treatment strategy were identified.

Results: A total of 192 of the 777 participants died during follow-up, including 94 (12.1%) of a CV cause, 59 (7.6%) of a non-CV cause, and 39 (5.0%) of an undetermined cause. The 3-year cumulative rates of CV death were similar between the invasive and conservative strategies (14.6% vs 12.6%, respectively; HR: 1.13, 95% CI: 0.75-1.70). Non-CV death rates were also similar between the invasive and conservative arms (8.4% and 8.2%, respectively; HR: 1.25; 95% CI: 0.75-2.09). Sudden cardiac death (46.8% of CV deaths) and infection (54.2% of non-CV deaths) were the most common cause-specific deaths and did not vary by treatment strategy.

Conclusions: In ISCHEMIA-CKD, CV death was more common than non-CV or undetermined death during the 3-year follow-up. The randomized treatment assignment did not affect the cause-specific incidences of death in participants with advanced CKD and moderate or severe myocardial ischemia. (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease [ISCHEMIA-CKD]; NCT01985360).

Citing Articles

Systemic Inflammatory Response Index (SIRI) is associated with all-cause mortality and cardiovascular mortality in population with chronic kidney disease: evidence from NHANES (2001-2018).

Gu L, Xia Z, Qing B, Wang W, Chen H, Wang J Front Immunol. 2024; 15:1338025.

PMID: 38558798 PMC: 10978803. DOI: 10.3389/fimmu.2024.1338025.


The potential association between influenza vaccination and lower incidence of renal cell carcinoma.

Marques da Silva B, Mayne K, Zakrocka I Clin Kidney J. 2023; 16(11):1714-1717.

PMID: 37915932 PMC: 10616471. DOI: 10.1093/ckj/sfad180.


ISCHEMIA-EXTEND studies: Rationale and design.

Anthopolos R, Maron D, Bangalore S, Reynolds H, Xu Y, OBrien S Am Heart J. 2022; 254:228-233.

PMID: 36206950 PMC: 9880872. DOI: 10.1016/j.ahj.2022.09.009.

References
1.
Wanner C, Krane V, Marz W, Olschewski M, Mann J, Ruf G . Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353(3):238-48. DOI: 10.1056/NEJMoa043545. View

2.
van Walraven C, Manuel D, Knoll G . Survival trends in ESRD patients compared with the general population in the United States. Am J Kidney Dis. 2013; 63(3):491-9. DOI: 10.1053/j.ajkd.2013.09.011. View

3.
Pickup L, Law J, Townend J, Ferro C . Sudden cardiac death in chronic renal disease: aetiology and risk reduction strategies. Nephrol Dial Transplant. 2019; 36(8):1386-1388. PMC: 8311576. DOI: 10.1093/ndt/gfz232. View

4.
Sarnak M, Amann K, Bangalore S, Cavalcante J, Charytan D, Craig J . Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019; 74(14):1823-1838. DOI: 10.1016/j.jacc.2019.08.1017. View

5.
Genovesi S, Valsecchi M, Rossi E, Pogliani D, Acquistapace I, De Cristofaro V . Sudden death and associated factors in a historical cohort of chronic haemodialysis patients. Nephrol Dial Transplant. 2009; 24(8):2529-36. DOI: 10.1093/ndt/gfp104. View